TOPLINE: The introduction of highly effective modulator (elexacaftor/tezacaftor/ivacaftor) therapy improved the disease trajectory of cystic fibrosis (CF). However, its benefits were less pronounced for lung transplant candidates of Black or Hispanic ethnicity than for those of White ethnicity. METHODOLOGY: Researchers evaluated the differences in lung transplantation outcomes by race/ethnicity in patients with CF using data ...
Copyright © glc. All Rights Reserved
